Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|7|584-591

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.7, 2015-07, pp. : 584-591

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 592-597

John Wiley & Sons Inc

Access to resources Recommend Favorite

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 577-583

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thrombocytosis Associated with Enzyme Replacement Therapy in Gaucher Disease

By  

Acta Haematologica, Vol. 108, Iss. 2, 2002-08 ,pp. : 94-96

Karger

Access to resources Recommend Favorite

Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

By vom Dahl Stephan   Poll Ludger   Di Rocco Maja   Ciana Giovanni   Denes Carmencita   Mariani Giuliano   Maas Mario  

Current Medical Research and Opinion, Vol. 22, Iss. 6, 2006-06 ,pp. : 1045-1064

Informa Healthcare

Access to resources Recommend Favorite

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 620-628

John Wiley & Sons Inc

Access to resources Recommend Favorite